About

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cardiac arrhythmias. The company is backed by leading institutional healthcare investors Deerfield Management and HealthCap. Incarda’s lead development program is a novel, orally inhaled formulation of flecainide intended for rapid treatment of recent-onset, symptomatic paroxysmal atrial fibrillation.